Combination of cytotoxic agents and targeted therapy for the treatment of advanced sarcomas: preclinical background and early clinical development
Year: 2016
Type: dissertation
Abstract: Sarcomas are a group of malignancies characterized by their bad prognosis and the absence of effective treatments. Median survival of advanced sarcoma patients is only one year in spite of treatment. Therefore, it is mandatory to identify new therapeutic strategies. Our hypothesis is that the inhibition of angiogenesis and the mTOR pathway in sarcomas in combination with active cytotoxic agents enhances each strategy alone without increase in toxicity.\n\n\t\t\t\t To confirm such hypothesis, we conducted two phase I trials with associated preclinical studies which have been published in international scientific journals.\n\n\t\t\t\t Article 1: Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.\n\n\t\t\t\t Background: This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma.\n\n\t\t\t\t Methods: Twelve sarcoma patients (9 soft-tissue, 3 bone sarcoma) were treated with sorafenib plus ifosfamide (starting doses 200 mg bid and 6 g/m(2) respectively). A 3 + 3 dose escalation design with cohorts of 3-6 patients was used. A study to assess the in vitro efficacy of the combination was also conducted.\n\n\t\t\t\t Results: Three DLTs were observed: fatigue grade 4 with sorafenib 400 mg bid plus ifosfamide 6 g/m(2) and encephalopathy and emesis grade 3 with sorafenib 400 mg bid plus ifosfamide 7.5 g/m(2). Other toxicities included diarrhea, hand-foot syndrome, mucositis, neutropenia, skin rash and thrombocytopenia. There were no relevant effects on PK of sorafenib but an increase in ifosfamide active metabolite 4-hydroxy-ifosfamide was observed. Eight patients achieved stable disease lasting more than 12 weeks. An additive effect was observed in vitro.\n\n\t\t\t\t Conclusions: RD was sorafenib 400 mg bid plus ifosfamide 6 g/m(2), allowing administration of active doses of both agents. Limited preliminary antitumor activity was also observed. A phase II study is currently ongoing.
Authors: Martín Liberal, Juan Jesús
Institution: Universitat de Barcelona
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2604433976
